An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Celon Pharma, a drug company, said a study showed their version of semaglutide — which they call Reduzek — behaves in the body the same way as an existing semaglutide product. In plain terms, their results suggest Reduzek delivers the drug into the bloodstream at the same speed and amount as the reference product. The company is framing this as a checkmark on the path toward getting approval and selling their version. Semaglutide is the active ingredient in medicines like Ozempic and Wegovy. It’s a man-made copy of a natural gut hormone that helps control appetite and blood sugar. In people it makes you feel fuller, can slow how fast your stomach empties, and affects signals to the brain that regulate hunger. It’s given by injection and is used for type 2 diabetes and for weight management under different brand names and doses. The announcement is about a “bioequivalence” study. That’s a standard test drug makers run to show a new product is effectively the same as a proven product in how much of the drug gets into the blood and how fast. These studies are usually done in healthy volunteers, not patients, and involve measuring drug levels over time. The snippet doesn’t give details like how many people were in the study, exact numbers, or whether regulators have reviewed the data. So while “positive bioequivalence” means the company met the technical criteria in that trial, it’s not the same as full regulatory approval or proof the new product is as safe or effective in real-world patients. Why this matters: if a company can prove bioequivalence, it can move toward regulatory approval to market a generic or biosimilar version. That can increase competition and potentially lower prices or increase supply of semaglutide products, which many people use for diabetes or weight management. Patients, prescribers, and health systems pay attention because more approved suppliers can make treatments more accessible or affordable over time. There are important caveats. Bioequivalence studies don’t test long-term safety or how well the medicine works in all patient groups. They usually involve a small number of healthy volunteers, not the diverse patients who will ultimately use the drug. Regulatory bodies still need to review the full data package before approval. And semaglutide itself has known side effects (like nausea, possible pancreatitis risk, and other issues) and is not suitable for everyone. The announcement doesn’t mean Reduzek is on the market yet or that it has been reviewed by regulators. Bottom line: Celon says their semaglutide matches an existing product in how it enters the bloodstream, which is a key step toward offering an alternative version, but more review and regulatory steps remain before it could affect patients or prices.
Source: TradingView